Aleva Neurotherapeutics
Latest round
- Series C
Last raised
- May 2016
Total raised
- $36M
Investors
- 7
About Aleva Neurotherapeutics
Founded in 2008 in Lausanne, Switzerland, Aleva Neurotherapeutics specializes in innovative solutions for neurological treatments. The company was co-founded by André Mercanzini and Claudio Pollo, with Alain Jordan as CEO.Aleva Neurotherapeutics specializes in the development and commercialization of advanced Deep Brain Stimulation (DBS) technologies aimed at treating neurological disorders, particularly Parkinson’s disease and essential tremor. The company’s flagship product, the directSTIM™ system, employs Directional Deep Brain Stimulation, which allows for precise targeting of brain regions responsible for motor control. This innovative approach is designed to enhance therapeutic benefits while minimizing side effects associated with traditional stimulation methods. Aleva’s technologies are specifically tailored to meet the needs of neurological professionals, including neurologists and neurosurgeons, who are focused on improving patient outcomes.Aleva Neurotherapeutics generates revenue through the sale of its directSTIM™ DBS systems and related components, which are primarily transacted through partnerships with leading neurological clinics and healthcare institutions. The transaction structure typically involves direct sales to hospitals, with potential for ongoing service agreements that include maintenance and support for the systems. Pricing strategies for the directSTIM™ system may involve tiered pricing based on volume purchases or specific institutional agreements, ensuring accessibility and support for healthcare providers. Upcoming launches include new iterations of the directSTIM™ system designed for improved patient outcomes. The company is targeting expansion into additional European markets and regions in North America by 2025. Recent developments include Kreos Capital acquiring Aleva Neurotherapeutics SA, which will support these growth initiatives.
Who invested in Aleva Neurotherapeutics
7 investors across 3 rounds
See all investors in Aleva Neurotherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Aleva Neurotherapeutics
Who invested in Aleva Neurotherapeutics?
Aleva Neurotherapeutics has 7 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Aleva Neurotherapeutics raised?
Aleva Neurotherapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Aleva Neurotherapeutics last raise money?
Aleva Neurotherapeutics's most recent round on record is a Series C, in May 2016.
What does Aleva Neurotherapeutics do?
Founded in 2008 in Lausanne, Switzerland, Aleva Neurotherapeutics specializes in innovative solutions for neurological treatments.
Where is Aleva Neurotherapeutics headquartered?
Aleva Neurotherapeutics is headquartered in Lausanne, Switzerland.
Which VCs invest in companies like Aleva Neurotherapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back medical devices & equipment companies at Aleva Neurotherapeutics's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series C
Raising like Aleva Neurotherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.